Printed from https://fiscalreceipts.com/program/0603807A/ — built September 26, 2026. Every figure is citation-backed; see the page online for per-number provenance.
Medical Systems - Adv Dev
Budget figures
FY2026 award data is a partial year — USAspending reports awards on a rolling basis, and this corpus runs through 2026-09-04. why partial FY2026 data? →
Budget trajectory
| Fiscal year | Amount |
|---|---|
| FY24 | $8.00M |
| FY25 | $582.0K |
| FY26 | $1.00M |
All series figures: R-1 TOA · PB2026
Decade view
P-1/R-1 workbook TOA basis, shown compact in $B/$M (the workbook records USD thousands); each figure cites its own President's Budget edition
The vertical scale does not start at zero: the baseline sits just below this program’s smallest year, so a low point on this line is not a small amount. Read the shape for direction and the grid below for the figures.
● actuals (line) · ○ enacted · ◇ request — gaps are editions the program is absent from, never interpolated.
| Series | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actuals | $22.8M | $39.7M | $47.3M | $36.3M | $38.4M | $36.3M | $36.0M | $27.8M | $5.60M | $8.00M | ||
| Enacted | $32.0M | $33.5M | $33.5M | $39.2M | $37.0M | $33.1M | $37.1M | $5.60M | $1.60M | $582.0K | ||
| Request | $33.5M | $33.5M | $34.3M | $31.2M | $28.5M | $22.1M | $598.0K | $1.60M | $582.0K | $1.00M |
blank = series not published for this year; – = absent from that edition.
Asked vs spent: the PB2017 book requested $33.5M for FY2017; the PB2019 book reported $47.3M as actual total obligation authority — $13.8M above the request. 47.3 − 33.5 = 13.8 USD millions — the compact figures above are rounded for reading.
Program lineage
No predecessor/successor lineage was recorded for this program element — no FY-to-FY transfer into or out of this line was stated in the ingested J-books, and none was inferred from the program structure.
Description
Mission — Medical Systems - Adv Dev
This Program Element (PE) funds development of medical materiel within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle using 6.4 (Advanced Component Development and Prototype) funding. Program efforts support transition of promising Science and Technology candidate medical technologies (drugs, vaccines, medical devices, diagnostics, and mechanisms for detection and control of disease carrying insects) to larger scale testing in humans for safety and effectiveness. Programs are aligned to meet future force requirements identified within concept documents and organizational structures. This PE also provides funding for Food and Drug Administration (FDA) regulated human clinical trials to gain additional information about safety and effectiveness on the path to licensure for use in humans. These efforts are managed by U.S. Army Medical Materiel Development Activity (USAMMDA) of the U.S. Army Medical Research and Development Command. The FY 2026 request was reduced by $0.003 million for civilian personnel to optimize the workforce in compliance with Executive Order 14210, "Implementing the President's Department of Government Efficiency Workforce Optimization Initiative."
Mission — DoD Drug & Vacc Ad
This Project funds development of candidate medical countermeasures for endemic infectious diseases of military relevance. These efforts are in: vaccines, drugs, diagnostic kits/devices. These funds support human clinical effectiveness (capacity to produce a desired size of an effect under ideal or optimal conditions) trials of the drug/vaccine in larger groups that are designed to assess how well the drug/vaccine works and continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits and devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis, and accelerated recovery time once diagnosed to enhance battlefield readiness. All clinical trials are conducted in accordance with United States (U.S.) Food and Drug Administration (FDA) regulations, a mandatory obligation for all military products placed into the hands of medical providers or service members. Product development priorities are determined based upon four major factors: (1) the extent and threat of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).
Mission — Field Medical Systems Advanced Development
This Project funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care. This Project funds human clinical trials to test the safety and effectiveness of biologics (products derived from living organisms) and devices necessary to meet medical requirements. The Project Manager (PM) also considers factors to reduce the medical logistics footprint through smaller weight, volume, and equipment independence from supporting materials. All clinical trials are conducted in accordance with U.S. FDA regulations. Products from this project will transition to PE 0604807A (Medical Materiel/Medical Biological Defense Equipment - Eng Dev) /Project 832 (Field Medical Systems Engineering Development).
Mission — Counterdrug, DDR, Sys Development & Demonstration
Supports the Secretary of Defense approved counterdrug advanced development efforts used in a major re-design of the Forensic Toxicology Drug Testing Laboratory (FTDTL) information management system used to test urine samples for the presence of illegal drugs. The Drug Testing Program - Client Collection System (DTP-CSS) is comprised of several variations of a desktop application used to select service members for random drug testing, prepare labels for urine specimen bottles, and print corresponding chain-of-custody documents. This Project will standardize DTP-CSS across all services and migrate it to a Web-based system.
Justification
Accomplishments & Planned Programs (2)
DoD Drug and Vaccine Advanced Development - Medical Readiness
Funding is provided for the development of candidate medical countermeasures for military relevant infectious disease focusing on prevention to increase medical readiness. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of drugs, vaccines, medical diagnostic kits and devices
Field Medical Systems Advanced Development - Medical Readiness
Funding is provided for engineering and manufacturing development of medical products for diagnostic devices and testing of medical devices for use in the field. This project provides for the advanced product development and prototyping of Army lifesaving medical field systems. Project supports development and testing of medical products and equipment for deployable forces providing future interoperability of systems on the battlefield and situational awareness of Soldier well-being. Project supports enhancements to Soldier battlefield effectiveness, survivability, and sustainment. This project also supports joint medical field systems and prolonged combat casualty care requirements.
Budget line items(workbook-cited)
P-1/R-1 workbook Total Obligation Authority basis (USD thousands) · PB2026.
Exhibit R-1
| Account | Org | Type | Amount |
|---|---|---|---|
| Research, Development, Test and Evaluation, Army | A | FY24 Actuals | $8.00M |
| Research, Development, Test and Evaluation, Army | A | FY25 Enacted | $582.0K |
| Research, Development, Test and Evaluation, Army | A | FY25 Total | $582.0K |
| Research, Development, Test and Evaluation, Army | A | FY26 Disc. Request | $1.00M |
| Research, Development, Test and Evaluation, Army | A | FY26 Total | $1.00M |
Budget Details(R-2/P-40 facts)
J-book detail basis (R-2/P-40, USD millions) · PB2026 — a different accounting basis from the P-1/R-1 workbook TOA above; where the two disagree, the reconciliation strip under Budget figures shows both.
Wider than this screen — swipe the table sideways for the remaining fiscal-year columns.
| Project | FY24 Actuals | FY25 Total | FY26 Base | FY26 Request |
|---|---|---|---|---|
| Program Element | $8.00M | $582.0K | $1.00M | $1.00M |
| 808: DoD Drug & Vacc Ad | $404.0K | $422.0K | $423.0K | $423.0K |
| 836: Field Medical Systems Advanced Development | $5.61M | $160.0K | $577.0K | $577.0K |
| FF4: Counterdrug, DDR, Sys Development & Demonstration | $1.98M | — | — | — |
Follow the dollar
No follow-the-dollar view — this program's awards haven't been crosswalked at high confidence (flows cover 312 of 1,938 programs). why coverage is partial? →
Awards
No awards are linked to this program element at high or medium confidence — the budget→award crosswalk only asserts links it can defend, and this line has none yet.
Lobbying mentions
No Senate LDA lobbying filing in the tracked data mentions this program element by code or alias.
Oversight
Department-level designation (not specific to this program)
GAO lists 5 high-risk areas for DOD as a whole. That designation covers the department, not Medical Systems - Adv Dev. No program-specific GAO finding for this line is in the ingested data. See the DOD oversight record.
Program dossier
No research dossier for this program — dossiers cover 50 of 1,938 programs, the largest fully J-book-detailed lines by FY2026 requested dollars. why no dossier here? →
Primary sources
Open any budget figure for its exact receipt. Verified line items lead with the highlighted government PDF; original spreadsheets download with their budget edition and exhibit in the filename.
Budget totals · TOA sources
FY2026 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J74
Complete workbook · unchanged saved copy. Saves as PB2026_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2017 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J68
Complete workbook · unchanged saved copy. Saves as PB2017_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2018 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J69
Complete workbook · unchanged saved copy. Saves as PB2018_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2019 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J70
Complete workbook · unchanged saved copy. Saves as PB2019_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2020 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J88
Complete workbook · unchanged saved copy. Saves as PB2020_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2021 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J94
Complete workbook · unchanged saved copy. Saves as PB2021_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2022 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J64
Complete workbook · unchanged saved copy. Saves as PB2022_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2023 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J65
Complete workbook · unchanged saved copy. Saves as PB2023_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2024 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J65
Complete workbook · unchanged saved copy. Saves as PB2024_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
FY2025 Department of Defense Budget: RDT&E Programs (R-1) · comptroller.war.gov
Exhibit R-1 · J65
Complete workbook · unchanged saved copy. Saves as PB2025_DoD_R-1_Research-Development-Test-Evaluation.xlsx.
Detailed budget justification
The related TOA spreadsheets above use a different accounting basis from R-2/P-40 detail. Their amounts are not assumed to match these detailed sources.
RDTE - Vol 2 - Budget Activity 4A · www.asafm.army.mil
PDF page 289